The new five -year data to Sotykt (Deucravacitinib) show consistent security and lasting rates of response in psoriasis with moderate to heavy plaque

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.